(IVZ) Invesco - Ratings and Ratios
Mutual Funds, Exchange Traded Funds, Private Funds
IVZ EPS (Earnings per Share)
IVZ Revenue
Description: IVZ Invesco
Invesco Plc (NYSE:IVZ) is a global investment management firm that provides a wide range of services to various clients, including retail, institutional, and high-net-worth individuals. The firms diverse client base includes public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds.
From a business perspective, Invescos key strength lies in its ability to manage separate client-focused equity and fixed income portfolios, as well as launch various investment products such as mutual funds, exchange-traded funds (ETFs), and private funds. The firms investment strategy is characterized by a global approach, investing in public equity and fixed income markets, as well as alternative markets like commodities and currencies.
To evaluate Invescos performance, some key performance indicators (KPIs) to consider are Assets Under Management (AUM), revenue growth, and profit margins. As of the latest available data, Invescos AUM is approximately $1.4 trillion. The firms revenue is primarily driven by management fees, which are a percentage of AUM. Other relevant KPIs include the firms net flows, which indicate the net influx or outflux of funds under management, and the mix of revenue streams, including management fees, performance fees, and other revenue sources.
In terms of financial health, Invescos market capitalization is around $9.5 billion, with a price-to-earnings (P/E) ratio of 17.00 and a forward P/E ratio of 11.61. The firms return on equity (RoE) is 5.49%, indicating a relatively modest return on shareholder equity. To further assess the firms financial performance, it would be essential to analyze its income statement, balance sheet, and cash flow statement.
From an operational perspective, Invescos ability to maintain a strong brand, attract and retain top talent, and adapt to changing market conditions will be crucial in driving long-term success. The firms global presence, with offices in Atlanta, Georgia, and Hamilton, Bermuda, provides a solid foundation for its international business.
IVZ Stock Overview
| Market Cap in USD | 10,387m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 1995-08-24 |
IVZ Stock Ratings
| Growth Rating | 47.9% |
| Fundamental | 68.0% |
| Dividend Rating | 60.6% |
| Return 12m vs S&P 500 | 14.0% |
| Analyst Rating | 3.07 of 5 |
IVZ Dividends
| Dividend Yield 12m | 3.63% |
| Yield on Cost 5y | 7.29% |
| Annual Growth 5y | 1.27% |
| Payout Consistency | 93.3% |
| Payout Ratio | 47.2% |
IVZ Growth Ratios
| Growth Correlation 3m | 90.4% |
| Growth Correlation 12m | 34.6% |
| Growth Correlation 5y | -19.3% |
| CAGR 5y | 20.84% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.57 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.53 |
| Sharpe Ratio 12m | 0.72 |
| Alpha | 7.10 |
| Beta | 1.629 |
| Volatility | 34.76% |
| Current Volume | 5444.8k |
| Average Volume 20d | 4159.2k |
| Stop Loss | 21.9 (-4.1%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (816.4m TTM) > 0 and > 6% of Revenue (6% = 369.2m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -28.04% (prev 154.6%; Δ -182.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.22b > Net Income 816.4m (YES >=105%, WARN >=100%) |
| Net Debt (392.0m) to EBITDA (1.31b) ratio: 0.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (453.8m) change vs 12m ago -0.50% (target <= -2.0% for YES) |
| Gross Margin 33.37% (prev 35.00%; Δ -1.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.11% (prev 21.40%; Δ 0.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.15 (EBITDA TTM 1.31b / Interest Expense TTM 59.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.17
| (A) -0.06 = (Total Current Assets 922.7m - Total Current Liabilities 2.65b) / Total Assets 28.50b |
| (B) 0.24 = Retained Earnings (Balance) 6.96b / Total Assets 28.50b |
| (C) 0.04 = EBIT TTM 1.14b / Avg Total Assets 27.83b |
| (D) 0.47 = Book Value of Equity 6.41b / Total Liabilities 13.54b |
| Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.98
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 10.55% = 5.0 |
| 3. FCF Margin 19.46% = 4.86 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda 0.30 = 2.43 |
| 6. ROIC - WACC (= -4.84)% = -6.05 |
| 7. RoE 5.64% = 0.47 |
| 8. Rev. Trend 78.76% = 5.91 |
| 9. EPS Trend 47.32% = 2.37 |
What is the price of IVZ shares?
Over the past week, the price has changed by -1.93%, over one month by +1.20%, over three months by +14.18% and over the past year by +32.74%.
Is Invesco a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IVZ is around 20.71 USD . This means that IVZ is currently overvalued and has a potential downside of -9.33%.
Is IVZ a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the IVZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.9 | 9.1% |
| Analysts Target Price | 24.9 | 9.1% |
| ValueRay Target Price | 23.5 | 2.8% |
Last update: 2025-10-15 03:50
IVZ Fundamental Data Overview
P/E Trailing = 25.043
P/E Forward = 10.4493
P/S = 1.688
P/B = 0.9693
P/EG = 0.5047
Beta = 1.629
Revenue TTM = 6.15b USD
EBIT TTM = 1.14b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 10.08b USD (from longTermDebt, last quarter)
Short Term Debt = 499.6m USD (from shortTermDebt, last quarter)
Debt = 1.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 392.0m USD (from netDebt column, last quarter)
Enterprise Value = 11.35b USD (10.39b + Debt 1.88b - CCE 922.7m)
Interest Coverage Ratio = 19.15 (Ebit TTM 1.14b / Interest Expense TTM 59.6m)
FCF Yield = 10.55% (FCF TTM 1.20b / Enterprise Value 11.35b)
FCF Margin = 19.46% (FCF TTM 1.20b / Revenue TTM 6.15b)
Net Margin = 13.27% (Net Income TTM 816.4m / Revenue TTM 6.15b)
Gross Margin = 33.37% ((Revenue TTM 6.15b - Cost of Revenue TTM 4.10b) / Revenue TTM)
Gross Margin QoQ = 33.28% (prev 36.33%)
Tobins Q-Ratio = 0.40 (Enterprise Value 11.35b / Total Assets 28.50b)
Interest Expense / Debt = 1.10% (Interest Expense 20.7m / Debt 1.88b)
Taxrate = 28.06% (77.0m / 274.4m)
NOPAT = 821.1m (EBIT 1.14b * (1 - 28.06%))
Current Ratio = 0.35 (Total Current Assets 922.7m / Total Current Liabilities 2.65b)
Debt / Equity = 0.14 (Debt 1.88b / totalStockholderEquity, last quarter 13.87b)
Debt / EBITDA = 0.30 (Net Debt 392.0m / EBITDA 1.31b)
Debt / FCF = 0.33 (Net Debt 392.0m / FCF TTM 1.20b)
Total Stockholder Equity = 14.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.86% (Net Income 816.4m / Total Assets 28.50b)
RoE = 5.64% (Net Income TTM 816.4m / Total Stockholder Equity 14.47b)
RoCE = 4.65% (EBIT 1.14b / Capital Employed (Equity 14.47b + L.T.Debt 10.08b))
RoIC = 5.45% (NOPAT 821.1m / Invested Capital 15.06b)
WACC = 10.30% (E(10.39b)/V(12.27b) * Re(12.02%) + D(1.88b)/V(12.27b) * Rd(1.10%) * (1-Tc(0.28)))
Discount Rate = 12.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF Debug] Terminal Value 69.60% ; FCFE base≈1.27b ; Y1≈1.57b ; Y5≈2.67b
Fair Price DCF = 55.69 (DCF Value 24.84b / Shares Outstanding 446.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 47.32 | EPS CAGR: 2.10% | SUE: -0.71 | # QB: 0
Revenue Correlation: 78.76 | Revenue CAGR: 1.73% | SUE: 0.81 | # QB: 0
Additional Sources for IVZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle